Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MTC-I
- Development stage
- Unknown
- Lead developer
- Biotts
- Modality
- Peptides
- Administration
- Transdermal
01
Overview
MTC-I (also referred to as MTC-Ins) is a transdermal insulin formulation developed by Biotts for the treatment of diabetes. The drug utilizes Biotts' proprietary MTC-Y (Multicomponent Transport System) technology, a skin-permeation-enhancing platform designed to enable the systemic delivery of large therapeutic molecules, such as peptides and proteins, through the skin. By providing a non-invasive alternative to traditional subcutaneous insulin injections, MTC-I aims to improve patient compliance and glycemic control. The program has advanced from preclinical development into Phase 1 clinical trials, where it is administered via a transdermal patch.
- Other names
- MTC-Insulintransdermal insulin
02
Targets
INSR (Insulin receptor)
Beyond the preview
Go deeper on MTC-I.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MTC-I.